-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Contrasting Aerovate Therapeutics (NASDAQ:AVTE) and Concert Pharmaceuticals (NASDAQ:CNCE)
Contrasting Aerovate Therapeutics (NASDAQ:AVTE) and Concert Pharmaceuticals (NASDAQ:CNCE)
Aerovate Therapeutics (NASDAQ:AVTE – Get Rating) and Concert Pharmaceuticals (NASDAQ:CNCE – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, profitability, risk and earnings.
Analyst Ratings
This is a summary of recent ratings and target prices for Aerovate Therapeutics and Concert Pharmaceuticals, as reported by MarketBeat.
Get Aerovate Therapeutics alerts:Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Aerovate Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Concert Pharmaceuticals | 0 | 0 | 3 | 0 | 3.00 |
Aerovate Therapeutics currently has a consensus price target of $40.50, indicating a potential upside of 61.68%. Concert Pharmaceuticals has a consensus price target of $19.67, indicating a potential upside of 178.96%. Given Concert Pharmaceuticals' higher possible upside, analysts plainly believe Concert Pharmaceuticals is more favorable than Aerovate Therapeutics.
Profitability
This table compares Aerovate Therapeutics and Concert Pharmaceuticals' net margins, return on equity and return on assets.Net Margins | Return on Equity | Return on Assets | |
Aerovate Therapeutics | N/A | -28.64% | -27.70% |
Concert Pharmaceuticals | N/A | -109.43% | -76.65% |
Valuation and Earnings
This table compares Aerovate Therapeutics and Concert Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Aerovate Therapeutics | N/A | N/A | -$22.96 million | ($1.57) | -15.96 |
Concert Pharmaceuticals | $32.58 million | 10.37 | -$80.05 million | ($3.21) | -2.20 |
Aerovate Therapeutics has higher earnings, but lower revenue than Concert Pharmaceuticals. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Concert Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Aerovate Therapeutics has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Concert Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500.
Insider & Institutional Ownership
70.6% of Concert Pharmaceuticals shares are owned by institutional investors. 17.8% of Aerovate Therapeutics shares are owned by company insiders. Comparatively, 11.3% of Concert Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Aerovate Therapeutics beats Concert Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
About Aerovate Therapeutics
(Get Rating)
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
About Concert Pharmaceuticals
(Get Rating)
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for Aerovate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerovate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Aerovate Therapeutics (NASDAQ:AVTE – Get Rating) and Concert Pharmaceuticals (NASDAQ:CNCE – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, profitability, risk and earnings.
好氧治疗(纳斯达克:AVTE-GET评级)和协和制药(纳斯达克:CNCE-GET评级)都是小盘医疗公司,但哪一家更好?我们将根据这两家公司的股息、估值、分析师建议、机构所有权、盈利能力、风险和收益的实力进行比较。
Analyst Ratings
分析师评级
This is a summary of recent ratings and target prices for Aerovate Therapeutics and Concert Pharmaceuticals, as reported by MarketBeat.
据MarketBeat报道,这是Aerovate治疗公司和Concert制药公司最近的评级和目标价格摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Aerovate Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Concert Pharmaceuticals | 0 | 0 | 3 | 0 | 3.00 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
充气治疗学 | 0 | 0 | 2 | 0 | 3.00 |
演唱会制药 | 0 | 0 | 3 | 0 | 3.00 |
Aerovate Therapeutics currently has a consensus price target of $40.50, indicating a potential upside of 61.68%. Concert Pharmaceuticals has a consensus price target of $19.67, indicating a potential upside of 178.96%. Given Concert Pharmaceuticals' higher possible upside, analysts plainly believe Concert Pharmaceuticals is more favorable than Aerovate Therapeutics.
Aerovate治疗公司目前的共识目标价为40.50美元,表明潜在涨幅为61.68%。Concert PharmPharmticals的共识目标价为19.67美元,表明潜在涨幅为178.96。考虑到Concert制药公司更高的可能上行空间,分析师们显然认为Concert制药公司比Aerovate治疗公司更有利。
Profitability
盈利能力
Net Margins | Return on Equity | Return on Assets | |
Aerovate Therapeutics | N/A | -28.64% | -27.70% |
Concert Pharmaceuticals | N/A | -109.43% | -76.65% |
净利润率 | 股本回报率 | 资产回报率 | |
充气治疗学 | 不适用 | -28.64% | -27.70% |
演唱会制药 | 不适用 | -109.43% | -76.65% |
Valuation and Earnings
估值和收益
This table compares Aerovate Therapeutics and Concert Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.
此表比较了Aerovate治疗公司和Concert制药公司的营收、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Aerovate Therapeutics | N/A | N/A | -$22.96 million | ($1.57) | -15.96 |
Concert Pharmaceuticals | $32.58 million | 10.37 | -$80.05 million | ($3.21) | -2.20 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
充气治疗学 | 不适用 | 不适用 | -2,296万元 | ($1.57) | -15.96 |
演唱会制药 | 3,258万美元 | 10.37 | -805万美元 | ($3.21) | -2.20 |
Aerovate Therapeutics has higher earnings, but lower revenue than Concert Pharmaceuticals. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Concert Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Aerovate治疗公司比Concert制药公司有更高的收益,但收入更低。Aerovate治疗公司的市盈率低于Concert制药公司,这表明它目前是两只股票中更负担得起的一只。
Volatility and Risk
波动性和风险
Aerovate Therapeutics has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Concert Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500.
Aerovate Treateutics的贝塔系数为0.8,这表明其股价的波动性比标准普尔500指数低20%。相比之下,Concert PharmPharmticals的贝塔系数为0.3,这表明其股价的波动性比标准普尔500指数低70%。
Insider & Institutional Ownership
内部人与机构所有权
70.6% of Concert Pharmaceuticals shares are owned by institutional investors. 17.8% of Aerovate Therapeutics shares are owned by company insiders. Comparatively, 11.3% of Concert Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Concert制药公司70.6%的股份由机构投资者持有。Aerovate治疗公司17.8%的股份由公司内部人士持有。相比之下,Concert PharmPharmticals 11.3%的股份由公司内部人士持有。强大的机构持股表明,对冲基金、捐赠基金和大型基金管理公司相信,一只股票有望实现长期增长。
Summary
摘要
Aerovate Therapeutics beats Concert Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
Aerovate治疗公司在两只股票比较的11个因素中有6个击败了Concert PharmPharmticals。
About Aerovate Therapeutics
关于Aerovate Treatetics
(Get Rating)
(获取评级)
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Aerovate治疗公司是一家临床阶段的生物制药公司,专注于开发能够改善美国罕见心肺疾病患者生命的药物。该公司专注于推进AV-101,这是一种治疗肺动脉高压的伊马替尼干粉吸入剂,目前处于2b期/3期试验。Aerovate治疗公司成立于2018年,总部设在马萨诸塞州沃尔瑟姆。
About Concert Pharmaceuticals
关于Concert制药公司
(Get Rating)
(获取评级)
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
康纳制药公司是一家临床阶段的生物制药公司,开发用于治疗自身免疫性疾病的新型小分子药物。该公司的主要候选产品是CTP-543,它正处于治疗斑秃的第三阶段临床试验,斑秃是一种严重的自身免疫性皮肤病。它与Avanir制药公司、Jazz制药公司、Cipla技术公司和Processa制药公司有战略合作。该公司成立于2006年,总部设在马萨诸塞州列克星敦。
Receive News & Ratings for Aerovate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerovate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Aerovate治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Aerovate治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧